Posts by ichor_developer

During Milwaukee Tech Week, a celebration for the regions emerging innovation and startup scene, Ichor Life Sciences CEO Kelsey Moody sat on a panel of judges for the Healthcare Innovation Pitch competition, where new companies had the opportunity to win cash prizes funded by the NIH and other regional sponsors. First place winners took home $10,000 for their company and received a years membership to the Matter startup incubator. Read more at the link below. https://www.bizjournals.com/milwaukee/inno/stories/news/2021/10/27/healthcare-innovation-pitch-competition-2021.html

Ichor Life Sciences (formerly Ichor Therapeutics), a premium pre-clinical contract research organization offering services in discovery through pharmacology, announces the publication of a peer-reviewed paper, “Kinetics of the multitasking high-affinity Win binding site of WDR5 in restricted and unrestricted conditions,” in a recent issue of Biochemical Journal. The paper was co-authored by researchers at Ichor Life Sciences and faculty from the Department of Physics at Syracuse University. The WD40 repeat protein 5 (WDR5) gene is a major drug target for cancer treatment as inhibition of WDR5 can kill cancer cells. At the same time, WDR5 plays a role in healthy cell function and participates in the formation of numerous protein complexes. The Ichor Therapeutics-Syracuse University team studied how WDR5 interacts with a specific protein called SET1. “This work will accelerate drug development because researchers will know how WDR5 interacts with different binding partners and can therefore intelligently design drugs to…

Ichor Life Sciences, a premium preclinical contract research organization offering services in discovery through pharmacology, announces the hiring of three PhDs to further strengthen its research and pharmacology offerings, effective immediately. Jaeide Jawahill, PhD is joining Ichor Life Sciences as a Postdoctoral Researcher, Discovery. In his position, Dr. Jawahill will focus on protein purification, biophysics, automation and data processing. Prior to joining Ichor, he held adjunct teaching positions with Clarkson University in Chemical Reactor Analysis and Chemical Engineering, and completed his dissertation using complex domain computations to carry out difficult distillation column simulations. He also held research and testing positions with Kraft Foods and Four Elements Environmental Inc. Dr. Jawahill completed his PhD in Chemical Engineering from Clarkson University, and will report to the organization’s R&D laboratory in Potsdam, New York. Madeline Masi, PhD is also joining Ichor Life Sciences as a Postdoctoral Researcher, Discovery. In her role, Dr. Masi…

LaFayette, N.Y. — Ichor Life Sciences, a premium preclinical contract research organization offering services in discovery through pharmacology, announces it has formally completed the acquisition of Woodland Biosciences, Inc. The in vivo services for the study of metabolic diseases and oncology provided by the former Woodland Biosciences are now available through Ichor’s Pharmacology division. A preclinical contract research organization, Woodland Biosciences was previously located on the campus of Tufts Veterinary Medicine School. Woodland’s R&D facilities have fully relocated from Tufts University to Ichor’s facilities in LaFayette, New York. Dr. Michael Briggs, the President and CSO of Woodland Biosciences, continues as part of Ichor’s scientific leadership in pharmacology. Dr. Briggs has deep expertise and experience in pharmacology and has worked on several preclinical and clinical programs in hepatitis, liver fibrosis and oncology, among others. Ichor Life Sciences’ clients and partners will continue to benefit from Dr. Briggs’ involvement in study designs…

Ichor Life Sciences, a premium pre-clinical contract research organization offering services in discovery through pharmacology, announces that its attending veterinarian, Danique Wortel, Doctor of Veterinary Medicine (DVM), now also serves as the primary attending veterinarian at Trudeau Institute. Established in Saranac Lake, New York, in 1884, Trudeau Institute is a not-for-profit research institute with a world-renowned reputation for R&D in immunity to infectious disease. As an attending veterinarian, Dr. Wortel is responsible for the health, well-being, and clinical care of animals used in research, testing, teaching, and production. Dr. Wortel is a graduate of Cornell University-College of Veterinary Medicine and holder of a certificate in lab animal medicine. She has extensive technical experience in laboratory animal husbandry, xenograft models, genetic models, and microsurgery. A hands-on practitioner, Dr. Wortel has pioneered best-in-class practices such as positive reinforcement training with lab animals and oversaw the buildout of four vivariums at Ichor Life…

Ichor Therapeutics is now known as Ichor Life Sciences. The new name reflects Ichor Life Sciences’ emphasis on delivering premium pre-clinical contract research and custom programs in discovery through pharmacology from its R&D facilities in LaFayette and Potsdam, New York. Ichor Life Sciences services customers in numerous therapeutic areas, with specific expertise in oncology, metabolic disease, geriatrics, ophthalmology, and musculoskeletal disease. The company includes two divisions, Ichor Discovery, which provides protein manufacturing and scientific expertise in protein expression, structural biology, and biophysics, and Ichor Pharmacology, which provides services such as in vitro testing, histology, PK/PD, in vivo toxicology, and in vivo efficacy. According to Dr. Kelsey Moody, PhD, MBA, and chief executive officer, several distinguishing factors contribute to the ongoing evolution and growth of Ichor Life Sciences: World-class R&D laboratories, delivered entirely stateside—highlighted by an AAALAC-accredited vivarium, Ichor’s facilities include in vivo imaging, x-ray irradiation, complete surgical capabilities, metabolic caging…

Ichor Life Sciences, Inc. (formerly Ichor Therapeutics) has expanded to the North Country Incubator at Clarkson University as an anchor tenant to establish a biotechnology cluster in Potsdam, N.Y. Ichor studies fundamental mechanisms of aging to develop new classes of drugs dedicated to helping people live longer, healthier lives. CEO and Founder Dr. Kelsey Moody, a native of the North Country, said he recognizes the unique opportunities for industry and academic collaborations and the entrepreneurial spirit of Clarkson. “Ichor aims to build upon obvious synergies between its core competencies in structure-based drug discovery and translational medicine, and Clarkson’s deep expertise in chemistry, engineering, and health sciences,” Dr. Moody said. In collaboration with the Lewis School for Health Sciences, Ichor is expanding their protein science division and will occupy offices and wet laboratory space in Peyton Hall. As part of the expansion, Ichor will provide over $2 million in state-of-the-art equipment…

News Release October 17th, 2019 Bethesda, MD: The third annual Geroscience Summit was organized by the Trans-NIH Geroscience Interest Group (GSIG). The Geroscience Summit is hosted by the National Institute of Health, and brings together interdisciplinary experts in the field of age-related diseases to bring their expertise to the field of geroscience. Geroscience seeks interdisciplinary experts in age-related diseases Geroscience is an emerging field that recognizes aging as the greatest risk factor for most chronic diseases and disabilities that affect older adults. This field’s mission is to first understand how aging allows for these diseases, then determine how to slow the progression of them. Traditional medicine generally specializes based on a single disease. For example, a cardiologist treats heart disease, and a dermatologist treats skin disease. However, the scientific community now believes diverse, age-associated diseases are caused by common underlying pathways. Even so, different disciplines don’t communicate with each other.…

News Release November 13, 2019 London, England: This year, the Global Innovation and New Technology (GIANT) Health Event took place on October 15 – 16 in London. This event brought thousands of pioneers among the health tech industry. Among them was Dr. Kelsey Moody, CEO at Ichor Life Sciences. Lysoclear develops a therapy to treat age-related macular degeneration Dr. Moody presented a talk titled “Towards enzyme augmentation therapy for macular degeneration.” During his presentation, Dr. Moody discussed recent progress at Lysoclear, an Ichor portfolio company. Lysoclear is developing an enzyme therapy to treat both age-related macular degeneration and Stargardt’s disease. Today, more than 200 million people worldwide are affected by these diseases. In 2018, Lysoclear demonstrated proof of concept that lipofuscin — a product of cell aging that is a risk factor for age-related macular degeneration — can be removed from the eye using enzyme therapy. This approach could establish…

News Release November 13, 2019 LaFayette, N.Y. — The American Association for Laboratory Animal Science‘s (AALAS) National Meeting is the largest meeting in the world dedicated to the care, production, and use of laboratory animals. This year Ichor was represented by Dr. Danique Wortel, DVM, attending veterinarian, and Dr. Forrest Wright, PhD, Operations Manager of Husbandry. Caring for aging mice presents unique challenges Dr. Wortel spoke on a panel hosted by The Jackson Laboratory (Jax). Her talk, titled “Managing Methuselah Mice: Adapting for the Aged,” focused on the unique challenges presented by caring for aging populations of mice. “Methuselah mice” is a reference to Methuselah — a Biblical figure said to have lived the longest of all individuals mentioned in the Bible. Research on geriatric animals is a growing focus area for companies and academic laboratories studying aging. Ichor and Jax are leaders in research involving aged animals. Dr. Wortel…